The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
about
Role of Positron Emission Tomography-Computed Tomography in Locally Advanced Breast CancerRole of positron emission tomography for the monitoring of response to therapy in breast cancerUsefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer.Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypesUtility of FDG-PET/CT in the evaluation of the response of locally advanced breast cancer to neoadjuvant chemotherapyThe role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PETEarly metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.Metabolic positron emission tomography imaging in cancer detection and therapy response.Breast conservation in locally advanced breast cancer.Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy.Comparison of the diagnostic performance of response evaluation criteria in solid tumor 1.0 with response evaluation criteria in solid tumor 1.1 on MRI in advanced breast cancer response evaluation to neoadjuvant chemotherapy.Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancerValue of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy.A molecular imaging primer: modalities, imaging agents, and applications.Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.Present and future role of FDG-PET/CT imaging in the management of breast cancer.¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.Circulating procalcitonin in aseptic carcinoma patients: a specificity study with (18)F-fluorodeoxyglucose positron-emission tomography/computed tomography as benchmark.¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer.Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis.Quantitative assessment of tumor blood flow changes in a murine breast cancer model after adriamycin chemotherapy using contrast-enhanced destruction-replenishment sonography.Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.
P2860
Q28079818-4D929EB1-3BEA-43E2-9469-95ABC7E2FF51Q28080621-AB05EE0D-EF74-46BF-A02A-FE1A1B1276FDQ33670107-3C2D01D5-AD75-418A-BBD1-4F420DB2F837Q33712925-BE986A17-92F6-46C0-BCA7-E7BE3D958D31Q33966252-D67CBF44-BE1B-4D5E-94CB-7AC13D297F95Q34048123-0C5A8623-71E3-44A4-89F7-9403400FCBF6Q34051790-0B2C7FB3-A051-4DEA-9328-E4C799ABAC20Q34257646-F4A4C6FA-1F4E-42C9-9DCB-1CCCEE7A1851Q34786518-7198812B-FA60-44E0-88FF-CFE3829384FEQ36169992-B37FCA6A-DC1A-46C8-9484-5C330696FB6BQ36508524-CAE56E08-9856-420A-A6A3-6D437B3E77A7Q36524335-C772B4E9-A1C1-4079-8F2E-CC3AB7BB3136Q36540092-183083EC-C17B-4CA3-B01D-36F5EE32E209Q37354718-C08CBF8E-F0DA-4445-891D-70232534C45AQ38005672-8B0640B2-12B7-45F2-BB60-155DCBD08B38Q38090509-D3A88928-1021-4369-A295-FC90661F7603Q38687620-D22A55B6-D225-4575-A03F-1ACF9530CF2CQ38693888-15721613-C229-40C7-8559-E9206897884BQ41721716-01E735B4-216F-4D5B-B767-AB77DDED4885Q42587608-84C62759-7136-4902-A002-D3762012109EQ43074699-DFCDCD42-FC91-4AA5-B3B1-8E27D43FF63AQ44090756-09B05E7F-70A8-48B7-AA55-6D2F99B769A3Q47941822-2DC0AA64-0C85-4AB1-87D8-576ED2D508BFQ47959144-FEF29D09-C27A-4DAF-BD62-BF24EDC046E4Q51347358-DEE5BF59-5D11-4F75-B1A2-A1270184917BQ51407617-B02C5B7E-C053-4E52-873B-FCB01D4B8D6DQ53115803-7A305AA8-C498-40EE-A483-79D6B11A56BDQ53122101-CABBA269-A8DB-4C76-A0DB-E75A278703E0Q53194326-FC476AEF-A083-4023-8FF3-804FF228D515Q53245198-C63C2AC5-6050-4090-A81F-40A71637088DQ53261275-EC014C24-2C3F-4627-A5E7-8827FC9C648A
P2860
The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The role of 18F-FDG PET/CT in ...... ocally advanced breast cancer.
@en
The role of 18F-FDG PET/CT in ...... ocally advanced breast cancer.
@nl
type
label
The role of 18F-FDG PET/CT in ...... ocally advanced breast cancer.
@en
The role of 18F-FDG PET/CT in ...... ocally advanced breast cancer.
@nl
prefLabel
The role of 18F-FDG PET/CT in ...... ocally advanced breast cancer.
@en
The role of 18F-FDG PET/CT in ...... ocally advanced breast cancer.
@nl
P2093
P1433
P1476
The role of 18F-FDG PET/CT in ...... ocally advanced breast cancer.
@en
P2093
Amandeep Kumar
Arun Malhotra
Madhavi Chawla
Rakesh Kumar
Sada Nand Mehta
Sidharatha Datta Gupta
Vathalaru Seenu
P2888
P304
P356
10.1007/S00330-009-1303-Z
P407
P577
2009-02-13T00:00:00Z